Literature DB >> 26513303

Compensation programs after withdrawal of the recommendation for HPV vaccine in Japan.

Koichiro Yuji1, Haruka Nakada2.   

Abstract

HPV vaccinations were recommended with the backing of a Japanese government subsidy program in 2010, and were included in the National Immunization Program in April 2013. However, the Ministry of Health, Labour, and Welfare withdrew the recommendation for the HPV vaccination in June 2013. We investigated HPV vaccine injury compensation programs for both the national and local governments. Approximately 3.38 million girls were vaccinated, and 2,584 complained of health problems. The majority of these received the vaccine shot as a non-routine vaccination. In total, 98 people developed health problems and applied for assistance from 2011 to 2014, but no cases have been processed since October 2014. Several local governments are providing their own compensation program for cases of vaccine adverse reactions, but the number is extremely low (16 of 1,741 municipalities and 1 of 47 prefectures). The local governments that are providing compensation are largely those where HPV vaccine victim support groups are prominent. The confusion regarding the national program for HPV vaccine injury was caused by the discrepancy between the compensation programs for those vaccinated under the immunization law and for those who received voluntary vaccinations. The establishment of a new compensation program might be key to finding a lasting resolution.

Entities:  

Keywords:  HPV; Japan; cervical cancer; compensation program; immunisation program; public health; vaccination; voluntary vaccines

Mesh:

Substances:

Year:  2015        PMID: 26513303      PMCID: PMC4963045          DOI: 10.1080/21645515.2015.1107686

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  7 in total

1.  HPV vaccination programme in Japan.

Authors:  Stuart Gilmour; Mikiko Kanda; Eiji Kusumi; Tetsuya Tanimoto; Masahiro Kami; Kenji Shibuya
Journal:  Lancet       Date:  2013-08-31       Impact factor: 79.321

Review 2.  No-fault compensation following adverse events attributed to vaccination: a review of international programmes.

Authors:  Clare Looker; Heath Kelly
Journal:  Bull World Health Organ       Date:  2011-03-21       Impact factor: 9.408

Review 3.  [The National Vaccine Injury Compensation Program in Japan].

Authors:  Toshiaki Ihara
Journal:  Nihon Rinsho       Date:  2011-09

4.  HPV vaccination crisis in Japan.

Authors:  Sharon J B Hanley; Eiji Yoshioka; Yoshiya Ito; Reiko Kishi
Journal:  Lancet       Date:  2015-06-27       Impact factor: 79.321

5.  Japan's failure to vaccinate girls against human papillomavirus.

Authors:  Yutaka Ueda; Takayuki Enomoto; Masayuki Sekine; Tomomi Egawa-Takata; Akiko Morimoto; Tadashi Kimura
Journal:  Am J Obstet Gynecol       Date:  2014-11-27       Impact factor: 8.661

Review 6.  Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus.

Authors:  Natalie Kash; Michael A Lee; Ramya Kollipara; Christopher Downing; Jacqueline Guidry; Stephen K Tyring
Journal:  J Clin Med       Date:  2015-04-03       Impact factor: 4.241

7.  Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.

Authors:  Heidi J Larson; Rose Wilson; Sharon Hanley; Astrid Parys; Pauline Paterson
Journal:  Hum Vaccin Immunother       Date:  2014-11-13       Impact factor: 3.452

  7 in total
  2 in total

1.  A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.

Authors:  Yan Yan Jia; Wei Jun Tan; Fei Fei Duan; Zhi Ming Pan; Xiang Chen; Yue Lan Yin; Xin An Jiao
Journal:  Front Cell Infect Microbiol       Date:  2017-06-29       Impact factor: 5.293

2.  Encouraging Cross-Disciplinary Collaboration and Innovation in Epidemiology in Japan.

Authors:  Hiroshi Yokomichi; Mie Mochizuki; Zentaro Yamagata
Journal:  Front Public Health       Date:  2021-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.